Krister Wennerberg
Krister Wennerberg
BRIC, University of Copenhagen
Verified email at
Cited by
Cited by
Rho and Rac take center stage
K Burridge, K Wennerberg
Cell 116 (2), 167-179, 2004
The Ras superfamily at a glance
K Wennerberg, KL Rossman, CJ Der
Journal of cell science 118 (5), 843-846, 2005
Rho-family GTPases: it's not only Rac and Rho (and I like it)
K Wennerberg, CJ Der
Journal of cell science 117 (8), 1301-1312, 2004
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
HLM Koskela, S Eldfors, P Ellonen, AJ van Adrichem, H Kuusanmäki, ...
New England Journal of Medicine 366 (20), 1905-1913, 2012
Integrin signaling to the actin cytoskeleton
KA DeMali, K Wennerberg, K Burridge
Current opinion in cell biology 15 (5), 572-582, 2003
A community effort to assess and improve drug sensitivity prediction algorithms
JC Costello, LM Heiser, E Georgii, M Gönen, MP Menden, NJ Wang, ...
Nature biotechnology 32 (12), 1202-1212, 2014
Fibronectin-integrin interactions
S Johansson, G Svineng, K Wennerberg, A Armulik, L Lohikangas
Frontiers in Bioscience-Landmark 2 (4), 126-146, 1997
Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins α11β1and α2β1
T Velling, J Risteli, K Wennerberg, DF Mosher, S Johansson
Journal of Biological Chemistry 277 (40), 37377-37381, 2002
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid LeukemiaISM Approach to Therapy Selection
T Pemovska, M Kontro, B Yadav, H Edgren, S Eldfors, A Szwajda, ...
Cancer discovery 3 (12), 1416-1429, 2013
Serine phosphorylation negatively regulates RhoA in vivo
SM Ellerbroek, K Wennerberg, K Burridge
Journal of Biological Chemistry 278 (21), 19023-19031, 2003
Searching for drug synergy in complex dose–response landscapes using an interaction potency model
B Yadav, K Wennerberg, T Aittokallio, J Tang
Computational and structural biotechnology journal 13, 504-513, 2015
Beta 1 integrin-dependent and-independent polymerization of fibronectin.
K Wennerberg, L Lohikangas, D Gullberg, M Pfaff, S Johansson, ...
The Journal of cell biology 132 (1), 227-238, 1996
Rnd proteins function as RhoA antagonists by activating p190 RhoGAP
K Wennerberg, MA Forget, SM Ellerbroek, WT Arthur, K Burridge, ...
Current Biology 13 (13), 1106-1115, 2003
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
HLM Rajala, S Eldfors, H Kuusanmäki, AJ Van Adrichem, T Olson, ...
Blood, The Journal of the American Society of Hematology 121 (22), 4541-4550, 2013
Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products
M Kibble, N Saarinen, J Tang, K Wennerberg, S Mäkelä, T Aittokallio
Natural product reports 32 (8), 1249-1266, 2015
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
B Yadav, T Pemovska, A Szwajda, E Kulesskiy, M Kontro, R Karjalainen, ...
Scientific reports 4 (1), 1-10, 2014
Axitinib effectively inhibits BCR-ABL1 (T315I) with a distinct binding conformation
T Pemovska, E Johnson, M Kontro, GA Repasky, J Chen, P Wells, ...
Nature 519 (7541), 102-105, 2015
Analysis of activated GAPs and GEFs in cell lysates
R García‐Mata, K Wennerberg, WT Arthur, NK Noren, SM Ellerbroek, ...
Methods in enzymology 406, 425-437, 2006
Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis
J Tang, A Szwajda, S Shakyawar, T Xu, P Hintsanen, K Wennerberg, ...
Journal of Chemical Information and Modeling 54 (3), 735-743, 2014
Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression
TK Hayes, NF Neel, C Hu, P Gautam, M Chenard, B Long, M Aziz, ...
Cancer cell 29 (1), 75-89, 2016
The system can't perform the operation now. Try again later.
Articles 1–20